BLRX BioLineRx Ltd. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1498403 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q2*2025-06-30 | 2024Q2*2024-06-30 | 2023Q2*2023-06-30 | 2022Q2*2022-06-30 | 2021Q2*2021-06-30 | 2020Q2*2020-06-30 | 2019Q2*2019-06-30 | 2018Q2*2018-06-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $304,000 | $5.39M | $0 | — | — | — | — | — |
| Cost of revenue | $72,000 | $897,000 | $0 | — | — | — | — | — |
| Gross profit | $232,000 | $4.50M | $0 | — | — | — | — | — |
| R&D expense | $2.33M | $2.23M | $3.01M | $5.39M | $5.14M | $4.64M | $5.30M | $4.48M |
| SG&A expense | $209,000 | $1.63M | $1.30M | $1.05M | $1.04M | $744,000 | $949,000 | $883,000 |
| Operating income | -$2.30M | -$5.77M | -$9.91M | -$7.60M | -$6.51M | -$5.57M | -$6.48M | -$5.73M |
| Interest expense | $276,000 | $2.08M | $1.34M | $379,000 | $242,000 | $396,000 | $440,000 | $11,000 |
| Net income | -$3.94M | $484,000 | -$18.55M | -$7.44M | -$6.84M | -$6.77M | -$5.49M | -$4.79M |
| EPS (basic) | 0.00 | 0.00 | -0.02 | -0.01 | -0.01 | -0.03 | -0.04 | -0.05 |
| EPS (diluted) | 0.00 | 0.00 | -0.02 | -0.01 | -0.01 | -0.03 | -0.04 | -0.05 |
| Weighted avg. shares (diluted) | — | 1.20B | 922.96M | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $7.19M | $9.62M | $10.10M | $14.00M | $17.48M | $5.52M | $4.97M | $5.79M |
| Receivables | $78,000 | $3.18M | — | — | — | — | — | — |
| Inventory | $2.85M | $3.63M | — | — | — | — | — | — |
| Current assets | $31.86M | $49.11M | $34.69M | $44.10M | $67.07M | $28.17M | $36.21M | $42.80M |
| PP&E, netmay include right-of-use assets (IFRS) | $197,000 | $344,000 | $648,000 | $810,000 | $1.14M | $1.58M | $2.05M | $2.32M |
| Intangibles | $10.41M | $13.69M | $22.01M | $21.70M | $21.71M | $21.75M | $21.93M | $7.04M |
| Total assets | $43.27M | $64.60M | $58.94M | $67.84M | $91.33M | $52.99M | $61.96M | $52.21M |
| Current liabilities | $15.48M | $30.52M | $12.45M | $9.63M | $9.92M | $11.72M | $8.56M | $5.34M |
| Short-term debt | $4.48M | $10.66M | $3.08M | $1.01M | $3.35M | $2.87M | $2.40M | $93,000 |
| Total liabilities | $23.20M | $50.62M | $37.88M | $11.27M | $17.44M | $23.76M | $20.18M | $6.03M |
| Shareholders' equity | $20.07M | $13.89M | $21.05M | $56.57M | $73.89M | $29.23M | $41.78M | $46.19M |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | — | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.